國家衛生研究院 NHRI:Item 3990099045/4603
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 967063      線上人數 : 817
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4603


    題名: Control of virus-\associated hemophagocytic syndrome by peroxisome proliferator activated receptor agonists in a rabbit model
    作者: Hsieh, WC;Lan, BS;Su, IJ
    貢獻者: Division of Clinical Research
    摘要: Hemophagocytic syndrome (HPS) is a fatal complication of severe viral infections such as Epstein-Barr virus (EBV) and recently, SARS CoV and H5N1 influenza. The pathogenesis of HPS is presumed to result from an enhanced Th1 cytokine secretion and systemic macrophage activation. Since peroxisome proliferators activated receptor (PPAR) agonists, regulators of cholesterol metabolism, have been shown to exhibit profound effects on the inhibition of proinflammatory cytokines and macrophage activation, rosiglitazone, a PPAR-gamma agonist, was adopted for the potential control of HPS using a rabbit model of Herpesvirus papio (HVP, an EBV homologue)-associated HPS. In vitro, rosiglitazone was shown to inhibit macrophage activation and secretion of tumor necrosis factor-alpha through inhibition of NFkB signaling in U937 cell line. Different doses of rosiglitazone were fed to rabbits after intravenous injection of 5 × 107 copies of HVP virus at different time courses (7 days and 20 days, respectively) of infection. As compared to the control group which succumbed consistently at around one month, the 4 mg rosiglitazone-treated group showed significant improvement of survival when fed at early stage (7 days) of infection (p < 0.01), while a higher dosage (8 mg) is needed to achieve therapeutic effect at advanced stage (20 days) of infection (p < 0.05). The viral load, TNF-alpha cytokine levels, and laboratory parameters also showed significant improvement in the rosiglitazone-treated group. Therefore, rosiglitazone, in addition to its therapeutic effect for metabolic syndrome, appears to represent a potential regimen for the control of HPS associated with virus infections.
    日期: 2008-12
    關聯: International Journal of Infectious Diseases. 2008 Dec;12:E168-E169.
    Link to: http://dx.doi.org/10.1016/j.ijid.2008.05.420
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1201-9712&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000263287800419
    顯示於類別:[蘇益仁(2002-2015)] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000263287800419.pdf56KbAdobe PDF485檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋